Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Sorbye H"" wg kryterium: Autor


Tytuł :
Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer:Nordic 8 results
Autorzy :
Pfeiffer, P
Glimelius, B
Winther, S
Qvortrup, C
Yilmaz, M
Berglund, À
Vistisen, K
Kersten, C
Liposits, G
Sorbye, H
Pokaż więcej
Źródło :
Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, À, Vistisen, K, Kersten, C, Liposits, G & Sorbye, H 2019, ' Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer : Nordic 8 results ', Annals of Oncology, vol. 30, no. Suppl. 4, O 015, pp. iv131 . https://doi.org/10.1093/annonc/mdz154.014
Tytuł :
NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)
Autorzy :
Winther, S. B.
Skuladottir, H.
Hofsli, E.
Shah, C-H.
Yilmaz, M. K.
Osterlund, P. J.
Berglund, A.
Glimelius, B.
Qvortrup, C.
Sorbye, H.
Pfeiffer, P.
Pokaż więcej
Źródło :
Winther, S B, Skuladottir, H, Hofsli, E, Shah, C-H, Yilmaz, M K, Osterlund, P J, Berglund, A, Glimelius, B, Qvortrup, C, Sorbye, H & Pfeiffer, P 2018, ' NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC) ', Annals of Oncology, vol. 29, no. Suppl. 8, pp. viii151 . https://doi.org/10.1093/annonc/mdy281.003
Tytuł :
Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy
Autorzy :
Hamfjord, J.
Guren, T.
Dajani, O.
Glimelius, B.
Sorbye, H.
Pfeiffer, P.
Christoffersen, T.
Lingjaerde, O.
Tveit, K.
Kure, E.
Pallisgaard, N.
Spindler, K.
Pokaż więcej
Źródło :
Hamfjord, J, Guren, T, Dajani, O, Glimelius, B, Sorbye, H, Pfeiffer, P, Christoffersen, T, Lingjaerde, O, Tveit, K, Kure, E, Pallisgaard, N & Spindler, K 2018, ' Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy ', Annals of Oncology, vol. 29, no. Suppl. 5, pp. v109 . https://doi.org/10.1093/annonc/mdy149.025
Tytuł :
Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Autorzy :
Ali, A. A.
Gronberg, M.
Hjortland, G. O.
Gronbaek, H.
Ladekarl, M.
Langer, S. W.
Welin, S.
Vestermark, L. W.
Osterlund, P.
Knigge, U.
Sorbye, H.
Janson, E. T.
Pokaż więcej
Źródło :
Ali, A A, Gronberg, M, Hjortland, G O, Gronbaek, H, Ladekarl, M, Langer, S W, Welin, S, Vestermark, L W, Osterlund, P, Knigge, U, Sorbye, H & Janson, E T 2018, ' Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3) ', Neuroendocrinology, vol. 106, no. Suppl. 1, pp. 184 .
Tytuł :
Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
Autorzy :
Kjellman, M.
Knigge, U.
Welin, S.
Gronbaek, H.
Thiis-Evensen, E.
Sorbye, H.
Joergensen, M. T.
Johanson, V
Si, Metso
Kj, Becker
Strom, T.
Belusa, R.
Pokaż więcej
Źródło :
Kjellman, M, Knigge, U, Welin, S, Gronbaek, H, Thiis-Evensen, E, Sorbye, H, Joergensen, M T, Johanson, V, Si, M, Kj, B, Strom, T & Belusa, R 2018, ' Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study ', Neuroendocrinology, vol. 106, no. Suppl. 1, pp. 155 .
Tytuł :
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Autorzy :
Galleberg, R B
Knigge, U
Tiensuu Janson, E
Vestermark, L W
Haugvik, Sven-Petter
Ladekarl, M
Langer, S W
Grønbæk, H
Österlund, Pia
Hjortland, G O
Assmus, J
Tang, L
Perren, A.
Sorbye, H
Pokaż więcej
Temat :
Chemotherapy, Adjuvant
Pancreatic Neoplasms/pathology
Ki-67 Antigen/analysis
Hepatectomy/adverse effects
Stomach Neoplasms/pathology
Intestinal Neoplasms/pathology
EXPERIENCE
CHEMOTHERAPY
Neoplasm Grading
Metastases
Kirurgia, anestesiologia, tehohoito, radiologia - Surgery, anesthesiology, intensive care, radiology
Carcinoma, Neuroendocrine/drug therapy
Survival Rate
Female
Catheter Ablation/adverse effects
ENETS CONSENSUS GUIDELINES
3122 Cancers
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
HEPATIC RESECTION
Liver
Survival
Neuroendocrine carcinoma
3126 Surgery, anesthesiology, intensive care, radiology
Aged
DIAGNOSIS
Middle Aged
G3
Liver Neoplasms/drug therapy
610 Medicine & health
Recurrence
TUMORS
Disease-Free Survival
MANAGEMENT
Journal Article
570 Life sciences
biology
LONG-TERM SURVIVAL
NEOPLASMS
Syöpätaudit - Cancers
Adult
Humans
Male
Surgery
Źródło :
Galleberg, R B, Knigge, U, Tiensuu Janson, E, Weber Vestermark, L, Haugvik, S-P, Ladekarl, M, Langer, S W, Grønbæk, H, Österlund, P, Hjortland, G O, Assmus, J, Tang, L, Perren, A & Sorbye, H 2017, ' Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas ', European Journal of Surgical Oncology, vol. 43, no. 9, pp. 1682-1689 . https://doi.org/10.1016/j.ejso.2017.04.010
Galleberg, R B, Knigge, U, Tiensuu Janson, E, Vestermark, L W, Haugvik, S-P, Ladekarl, M, Langer, S W, Grønbæk, H, Österlund, P, Hjortland, G O, Assmus, J, Tang, L, Perren, A & Sorbye, H 2017, ' Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas ', European Journal of Surgical Oncology, vol. 43, no. 9, pp. 1682-1689 . https://doi.org/10.1016/j.ejso.2017.04.010
Opis pliku :
fulltext; application/pdf
Tytuł :
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
Autorzy :
Niederle, B
Toumpanakis, C
Garcia-Carbonero, R
O'Toole, D
Anlauf, M
Sorbye, H
Raymond, E
Caplin, M
Perren, Aurel
Sedlackova, E
Cwikla, J B
Wiedenmann, B
Baudin, E
Pokaż więcej
Temat :
610 Medicine & health
570 Life sciences
biology
Źródło :
Garcia-Carbonero, R; Sorbye, H; Baudin, E; Raymond, E; Wiedenmann, B; Niederle, B; Sedlackova, E; Toumpanakis, C; Anlauf, M; Cwikla, J B; Caplin, M; O'Toole, D; Perren, Aurel (2017). ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology, 103(2), pp. 186-194. Karger 10.1159/000443172
Opis pliku :
application/pdf

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies